Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Plasma cell leukemia. Study of 10 cases].

A López Guillermo, J M Martí, J Bladé

    Sangre
    |February 1, 1989
    PubMed
    Summary

    This study analyzed 10 patients with plasma cell leukemia, a rare and aggressive form of multiple myeloma. The patients were treated at the University Hospital of Barcelona over 18 years. Five cases were primary, and five were secondary. Common symptoms included anemia, low platelet count, and bone marrow infiltration. Most patients had bone damage and some had liver involvement. Eight patients received chemotherapy, but only two had a partial response. The median survival was less than one month, and all secondary cases died within two months. Infections, kidney failure, and liver failure were the main causes of death. The study highlights the poor outcomes and limited treatment options for this severe condition.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

    Leukemia·2020
    Same author

    Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

    Leukemia·2015
    Same author

    Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.

    Bone·2013
    Same author

    The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.

    Leukemia research·2011
    Same author

    Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.

    Annals of oncology : official journal of the European Society for Medical Oncology·2009
    Same author

    Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.

    Annals of oncology : official journal of the European Society for Medical Oncology·2004

    Area of Science:

    • Hematology oncology
    • Myeloma and plasma cell disorders
    • Clinical hematology

    Background:

    Plasma cell leukemia is a rare and aggressive variant of multiple myeloma. Prior research has shown that it is associated with poor prognosis and limited treatment options. No prior work had resolved the full extent of clinical features and outcomes in a small cohort of patients. This gap motivated a retrospective analysis of cases to better understand disease presentation and response to therapy. Researchers have long noted the rarity of the condition, which complicates the development of standardized treatment protocols. The disease often presents with severe bone marrow infiltration and systemic complications. Understanding the natural history of the disease is essential for improving clinical management. The study aimed to contribute to the limited body of evidence on this aggressive malignancy.

    Purpose Of The Study:

    The purpose of the study was to analyze the clinical features and outcomes of 10 patients with plasma cell leukemia. The researchers focused on understanding disease presentation and treatment responses in a small cohort. They aimed to identify patterns in diagnosis, complications, and survival. The study was motivated by the need to better characterize this rare and severe condition. The researchers sought to determine whether existing chemotherapy regimens could improve outcomes. They also aimed to describe the frequency of complications such as infection and organ failure. The study was designed to provide insights into the natural history of the disease. These findings may help inform future treatment strategies for plasma cell leukemia.

    Keywords:
    Plasma cell leukemiaMultiple myelomaHematology oncologyChemotherapy outcomes

    Frequently Asked Questions

    The median survival was less than one month, with a range of 0.2 to 14 months.

    Regimens included vincristine, prednisone, melphalan, cyclophosphamide, adriamycin, and BCNU.

    The authors suggest that secondary PCL may be more aggressive and less responsive to treatment.

    Infections, renal failure, and liver insufficiency were the primary causes of death.

    Two patients achieved objective responses, lasting 10 and 3 months.

    Related Experiment Videos

    Main Methods:

    The study was a retrospective analysis of 10 patients diagnosed with plasma cell leukemia over 18 years. Data were collected from medical records at the University Hospital of Barcelona. Researchers categorized cases as primary or secondary based on clinical history. They evaluated laboratory findings, including blood counts and bone marrow infiltration. Imaging and clinical notes were reviewed for osteolytic lesions and organ involvement. Chemotherapy regimens were documented for each patient. Researchers tracked treatment responses and survival times. The study focused on describing clinical outcomes and complications.

    Main Results:

    The median survival for all 10 patients was less than one month, ranging from 0.2 to 14 months. Eight patients received chemotherapy including vincristine and prednisone. Six of these also received alkylating agents like melphalan and cyclophosphamide. Four patients received additional drugs such as adriamycin and BCNU. Only two patients achieved objective responses, lasting 10 and 3 months. The remaining six patients did not respond to treatment. All secondary PCL patients died within 2 months of diagnosis. Infections, renal failure, and liver insufficiency were the main causes of death.

    Conclusions:

    The study suggests that plasma cell leukemia is associated with a very poor prognosis. The authors propose that current treatment regimens offer limited benefit. The findings indicate that secondary PCL has an especially poor survival rate. The researchers suggest that infections and organ failure are major contributors to mortality. They propose that more effective therapies are needed for this aggressive disease. The study highlights the need for further research into treatment options. The authors suggest that early diagnosis may improve outcomes. The study supports the view that plasma cell leukemia remains a challenging condition to manage.

    The study suggests that the prognosis is very poor, with limited benefit from current treatments.